Genentech and NVIDIA enter into strategic AI research collaboration
Both companies will use their platforms to accelerate drug discovery and development
Read More
Tag: Genentech
Oncimmune partners with Genentech to profile samples from rheumatology trials
UK-headquartered company will characterise autoantibody profiles of clinical trial patients
Read More
Genentech’s Gavreto cleared for RET non-small cell lung cancer
The personalised cancer treatment has received conditional approval in the US
Read More
Tecentriq misses mark in ovarian cancer trial
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
Read More
Bicycle, Roche collab for immuno-oncology therapies
Under the terms of the agreement, the companies will collaborate on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.
Read More
Roche’s Genentech inks deal with Sosei Heptares
Under the terms of the agreement, Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments.
Read More
Roche’s ipatasertib combo shows early promise in triple-negative breast cancer
The results showed a 73% overall response rate irrespective of PD-L1 status.
Read More
FDA places partial hold on clinical trials of venetoclax for multiple myeloma
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
Read More
Roche and Genentech take global macular degeneration step
Roche and Genentech have initiated two large global Phase III clinical trials testing the potential of faricimab in wet age-related macular degeneration.
Read More
Roche’s Hemlibra shows sustained bleed control in children
Roche’s Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Read More
Genentech acquires Jecure Therapeutics
Roche group Genentech is acquiring San Diego-based biotech Jecure Therapeutics.
Read More
US approves first-in-class flu drug
The US Food and Drug Administration has approved Roche/Shionogi & Co’s Xofluza for the treatment of acute uncomplicated flu, opening the door to the first new antiviral with a novel mechanism of action in nearly 20 years.
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
